|Bid||0.00 x 4000|
|Ask||0.00 x 4000|
|Day's range||28.30 - 29.40|
|52-week range||28.30 - 54.93|
|Beta (5Y monthly)||0.56|
|PE ratio (TTM)||15.80|
|Earnings date||29 Jan 2024 - 02 Feb 2024|
|Forward dividend & yield||1.64 (5.67%)|
|Ex-dividend date||09 Nov 2023|
|1y target est||40.10|
Sign up now to see all the the picks and follow the 'Beat the S&P 500' strategy for up to 60% off for a limited time only!
Pfizer (NYSE: PFE), known for its billion-dollar coronavirus products -- the vaccine Comirnaty and the treatment Paxlovid -- saw its shares drop about 40%. This includes Pfizer's newer programs and what they may deliver in the future, as well as the company's valuation today. Is Pfizer a buy right now -- or a stock to avoid?
One stock I'm considering letting go is pharma giant Pfizer (NYSE: PFE). Here are two other issues driving me toward hitting the "sell" button on this pharma stock. Since Albert Bourla took over as CEO in 2019, Pfizer has been on a buying spree.